{"classes":[{"categories":[{"measurements":[{"comment":"No participants experienced an event and DOR was not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Tumor assessment was performed using RANO criteria for Participants with LGG.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Low Grade Glioma","id":"OG000","title":"Low Grade Glioma"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).","reportingStatus":"POSTED","timeFrame":"From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)","type":"SECONDARY","unitOfMeasure":"Months"}